Table 2.
Actively recruiting CAR T-cell trials for relapsed B-cell lymphomas using tumor antigen targets other than CD19
| Target | ClinTrials.gov identifier | Institution/sponsor | Age criteria (y) | Phase | Results reported (Y/N) |
|---|---|---|---|---|---|
| CD20 | NCT03277729 | Fred Hutchinson Cancer Research Center, Seattle, WA | ≥18 | 1/2 | N |
| NCT04316624 | Institute of Hematology and Blood Diseases Hospital, Tianjin, China | 18-75 | 1 | N | |
| NCT04169932 | First Affiliated Hospital with Nanjing Medical University, Jiangsu, China | 18-70 | 1 | N | |
| NCT04036019* | Shanghai Tongji Hospital, Tongji University School of Medicine, Shanghai, China | 14-70 | 1 | N | |
| CD22 | NCT04088890 | Stanford Medical Center, Stanford, CA | ≥18 | 1/1b | N |
| NCT04088864* | Stanford Medical Center, Stanford, CA | 1-30 | 1 | N | |
| NCT02650414* | Children’s Hospital of Philadelphia, Philadelphia, PA | 1-24 | 1 | Y (in ALL cohort) Ruella et al, 201725 | |
| NCT03262298 | Affiliated Hospital to Academic of Military Medical Sciences, Beijing, China | 18-65 | 1/2 | N | |
| NCT04007978* | Union Hospital, Tongji Medical College, Hubei, China | 14-70 | 1 | N | |
| Dual target: CD19/CD20 | NCT04186520 | Medical College of Wisconsin and Froedtert Hospital, Milwaukee, WI | ≥18 | 1/2 | N |
| NCT04007029 | UCLA/Jonsson Comprehensive Cancer Center, Los Angeles, CA | 18-70 | 1 | N | |
| NCT04215016 | Fujian Medical University, Fujian, China | ≥18 | 1 | N | |
| NCT03881761* | Cancer Hospital Affiliate to Zhengzhou University and Henan Cancer Hospital, Henan, China | 17-70 | 1 | N | |
| NCT03097770* | Chinese PLA General Hospital, Beijing, China | 16-70 | 1/2 | Y (74% CR) Zhang et al, 202032 | |
| Dual target: CD19/CD22 | NCT03233854 | Stanford University School of Medicine, Palo Alto, CA | ≥18 | 1 | N |
| NCT04204161* | Xiangya Hospital Central South University, Hunan, China | 1 mo to 18 y | 1 | N | |
| Dual target: CD19/CD22+ anti-PD1 Ab | NCT03287817 | Autolus Therapeutics | ≥18 | 1/2 | Y (55% CR) Osborne, 202046 |
| Dual target: CD19/CD20 or CD19/CD22 | NCT03398967* | Chinese PLA General Hospital, Beijing, China | 12-70 | 1/2 | N |
Ab, antibody; ALL, acute lymphoblastic leukemia; PLA, People’s Liberation Army; UCLA, University of California, Los Angeles.
*
Trials enrolling pediatric/adolescent patients.